Summary：**Dolphin Medical Services Announces Exciting Open Offer Date for July 17, 2026***July 12, 2025 –* D

**Dolphin Medical Services Announces Exciting Open Offer Date for July 17, 2026**

*July 12, 2025 –* Dolphin Medical Services (DMS) confirmed today that its highly anticipated open offer will launch on July 17, 2026, inviting both institutional and retail investors to acquire newly issued shares at a predetermined price. The announcement, made during a virtual press briefing led by Chief Executive Officer Dr. Elena Marquez, outlines the company’s strategy to raise capital for expansion into emerging markets, accelerate research‑and‑development pipelines, and strengthen its digital health infrastructure.

**Key Developments**
The open offer will allocate 15 million new shares, representing approximately 12 % of DMS’s post‑offer equity. Pricing is set at $28.50 per share, a 4 % premium to the average closing price over the past six months, reflecting confidence in the firm’s recent performance. Proceeds are earmarked for three primary initiatives: (1) establishing outpatient clinics in Southeast Asia and Sub‑Saharan Africa, (2) funding a multi‑year AI‑driven diagnostics program, and (3) upgrading telemedicine platforms to comply with upcoming interoperability standards set by the Office of the National Coordinator for Health Information Technology. Dr. Marquez emphasized that the timing aligns with a projected rebound in global healthcare spending, which the World Bank forecasts to reach $12 trillion by 2027.

**Industry Analysis**
Analysts note that DMS’s move comes amid a wave of consolidation among mid‑size medical service providers seeking scale to negotiate better reimbursement rates. A recent report by HealthTech Insights indicates that companies investing in AI diagnostics and telehealth have outperformed peers by an average of 8 % in total shareholder return over the last three years. Furthermore, the open offer structure—allowing existing shareholders to pre‑emptively purchase shares before public trading—helps mitigate dilution concerns while rewarding loyal investors. Competitors such as MediCore Group and VitaHealth have announced similar capital raises, suggesting a sector‑wide trend toward financing innovation through equity markets rather than debt.

**Future Outlook**
If the open offer meets its subscription target, DMS anticipates a net cash inflow of roughly $428 million. Management projects that the new clinics will generate $150 million in